




Cape Metropolitan



Western Cape Area



Newsletter

The Vanishing Art of Personalised Family Medicine

A quiet but profound shift is taking place in healthcare: the traditional family practitioner is slowly fading into the fog of history.

From Unhurried Care to Digital Detachment

Many doctors whose training and early years of practice belonged to the baby boomer era are quietly disappearing from the healthcare system.

With them goes a legacy of personalised care, empathy, continuity, and deep knowledge of families across generations.



Even some younger millennial doctors still remember a world of BlackBerry phones, iPods, and brick-sized cell phones with pull-up aerials. With this limited technology, Family Practitioners saw patients face-to-face for a full 20-minute consultation: a careful history, a hands-on examination, a personalised treatment plan and where necessary a referral to a specialist who would see, assess, treat and return the patient to your ongoing care...

Inside this issue

- The Vanishing Art of Personalised Family Medicine pg 1,5,8-9
- Worcester Open Day Event 2026 pg 2
- Another Huge success CPC/Qualicare Open Day 6 June 2026 pg10,17,20,22,25,28,31,34,37,40,43,46,48,50
- Cape Town Open Day 2026 Performance as assessment pg 13-14
- Pathcare News: RESPIRATORY PATHOGEN STATISTICS pg 42
- A giant of medicine, failed by justice pg 51-52
- Invitation to Dentists, Physiotherapists and Allied Health Care Professionals to become an Associate Member of CPC/Qualicare pg 55
- Qualicare Electronic Doctor Network pg 56-57
- Docweb Traffic pg 58



The Vanishing Art of Personalised Family Medicinecontinue to page 5

QualiCare

Worcester Open Day Event 25 July 2026

TOPICS WILL INCLUDE:

- Latest information on GP-specific medical conditions
 - Essential feedback on OHSC / NHI / Harmful Business Practices update / latest HPCSA Rules for Business Practice / dedicated workshop on AI, scribes, practice safety in banking, phishing, vishing / POPI updates
-

VENUE: WORCESTER FACULTY OF MEDICINE AND HEALTH SCIENCES,
STELLENBOSCH UNIVERSITY, CAMPUS, 1 DURBAN STREET, WORCESTER, 6849

FREE FOR MEMBERS & SHAREHOLDERS
R450.00 INCL. VAT FOR NON - CPC MEMBERS

SATURDAY
10HR00 FOR
10HR30 -18HR30

25

JULY
2026

- ✓ CPD Points will be awarded !
- ✓ Excellent lectures !!
- ✓ Great Food & interactive environment with exhibitors
- ✓ An opportunity to connect in person with your colleagues !
- ✓ Legendary superb prize giving!!

MACLEODS



Challenging Frontiers in Healthcare

UP TO
35%
SAVING⁴

**DUAL-ACTION RELIEF
THAT LASTS 24 HOURS.¹**

R77,23
(incl. VAT)⁴



R231,69
(incl. VAT)⁴



**Rupatadine delivers dual-action relief -
combining antihistaminic action with
targeted PAF inhibition to reduce
inflammation.²**

**The Better Choice for allergic rhinitis³,
now more affordable.**



For the use of a Registered Medical Practitioner, Hospital or Laboratory only.
For full prescribing information please refer to the Professional Information approved by the South African Health Products Regulatory Authority.

References:

1. Raputeze approved SAHPRA Professional Information (PI), 26 November 2024.
2. Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. *Allergo J Int* 2014; 23: 87–95. DOI: 10.1007/s40629-014-0011-7.
3. Sailaxmi V et al. Comparative evaluation of safety and efficacy of oral Rupatadine with oral Fexofenadine in patients of seasonal allergic rhinitis. *Perspectives in Medical Research*. September – December 2016, Vol4, Issue 3.
4. Versus other Rupatadine's. Pharmaceuticals Economic Evaluation Unit email dated 1 December 2025.

HCR: Abex Pharmaceutica (Pty) Ltd, Suite C, Rubenstein Ridge, 617 Rubenstein Drive, Moreleta Park, 0181. Tel: 012 997 6974

Marketed by: Macleods Pharmaceuticals SA (Pty) Ltd. Ground Floor, Office Block 1, Bassonia Estate Office Park (East), 1 Cussonia Drive, Bassonia Rock, Ext 12, Alberton, Gauteng, South Africa, 2061. Tel: +27 11 682 1169

Care was personal. Time was available. The doctor-patient relationship mattered.

A New Generation in a Different System

Today's Gen Z patients and doctors have entered a system in which personalised medical care has been turned on its head. Practitioners are expected to be accepting of electronic systems, rules and regulations of designated service provider networks, telephonic and video consultations as well as remote management, not to mention the myriads of complex benefit structures and designs!

Medical aid funders now issue lengthy benefit documents, often buried in exhausting PDF files on websites. Patients from similar backgrounds, and often from the same extended families, find themselves on different plans, receive different benefits, and even different qualities of medication, depending largely on what plan they can afford.

The result is a fragmented system that is difficult for doctors and patients to navigate.

The system has become more technical, but not necessarily more human.



Patients and Doctors are Lost in a Maze of Rules

Older patients, many of whom must rely on the private sector for ongoing care as the state hospitals leave much to be desired, are increasingly confused by a highly impersonal, box-ticking medical aid environment. They are often left feeling lost in a system that appears more focused on administration than care.



New practitioners entering the system, and who are understandably inexperienced in dealing with funder requirements, accept complex network conditions in order to qualify for direct payment of benefits when servicing medical aid members. These conditions include sub-limits, self-payment thresholds, designated networks, generic treatment plans, and summary expulsion from these networks should you transgress any of the myriad terms.

Doctors are being asked to care deeply while working inside systems that often reward detachment.

The Cost Spiral and the Specialist Disconnect

The rush by funders to automate healthcare and contain costs has been further complicated and influenced by the extremely high fees charged by private hospitals and aspects of the expensive specialist sector. Yet many medical aids still allow patients to refer themselves directly to specialists. Once a patient enters specialist care, many primary healthcare doctors are left out of the communications loop. The family practitioner is often not informed that the patient was admitted, underwent a procedure, received new medication, or was discharged. Routine long-term follow-up visits are scheduled with specialists when they could be managed by the family practitioner at a far lower cost.

When the family doctor is excluded, continuity of care is broken.



Practice Management & Medical Billing made simple

www.elle.health



Earn up to R2000
Join our referral program and start earning!

Dedicated Support

Efficient & effective guidance for your practice



Call Centre & On-Site Support

Known for our excellent after-sales services. Our professional and friendly team will be able to assist you with any of your claim queries.

About Elle Health

With more than 30 years of experience, we are your go-to, easy-to-use and intelligent online practice management assistant.



Web-based Practice Management Application

We are here to enhance your office efficiency, reduce payment times and save you money! Direct online integration with Medprax.


Get in Touch

hello@elle.health 0861 00 elle (0861 00 3553)

@ellehealthza


FREE Telehealth

with our elle connect patient APP



KEEP MOVING WITH EASE

IMPROVES MOBILITY



BUILDS HEALTHY CARTILAGE

REDUCES STIFFNESS & SWELLING



OSTEOEZE®

THE JOINT SPECIALIST

SO OSTEOEZE® GOLD. Per capsule: Glucosamine sulfate 500 mg; Chondroitin sulfate 267 mg; Vit C 50 mg; Manganese 1 mg, D.3.5 Connective Tissue Medicine: Other - Health Supplement. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. Nativa (Pty) Ltd | www.nativa.co.za | 260 Cradock Avenue, Lyttelton, Centurion, 0157, Gauteng, South Africa Customer | Tel Number: +27 860 628 482 | Customer Care e-mail: health@nativa.co.za | YPOST202606/001

The result is waste: duplicate investigations, unnecessary inter-specialist referrals, and a delayed return to coordinated primary care and significant uncurtailed costs!

The Younger Patient and the Medical Aid Dilemma

A worrying trend is emerging among younger millennial patients. Many are reluctant to join traditional medical aids and instead choose insurance-based products, which are not regulated in the same way as medical schemes. This decision is often driven by the rising cost of remaining within the medical aid system.

Gen Z patients often choose hospital plans only, at least until their first child arrives. They may then move temporarily to more comprehensive maternity cover before returning to a hospital plan once their family is complete. Late joiner penalties do not seem to deter this behaviour!

The principle of cross-subsidisation — the healthy supporting the sick, and the young supporting the old — is increasingly misunderstood or ignored.



Preventative Care: The Missing Foundation

Preventative healthcare remains poorly understood and undervalued both by patients and by funders!

Early intervention is too often neglected, contributing to younger patients presenting with advanced breast, bowel, pancreatic, gynaecological, and urological cancers.

Awareness campaigns and chatbots cannot replace careful, unrushed, personalised family medicine.

Family medicine is uniquely placed to understand patients in the context of their histories, families, relationships, pressures, and interdependencies. This holistic view is difficult to achieve in a mainly hospital-based environment, where care is often episodic and fragmented.

So What Is the Solution?

Change must come from the profession, not only from administrators. Funders have shifted from being payers of to financially motivated gatekeepers of primary care, often without the same medico-legal responsibility carried by clinicians.

Population Health Management and personalised healthcare plans have real merit when they are written and overseen by primary care physicians. Scheme design should support a practitioner's clinical judgement, not replace it.

General practice must once again become the conductor of the Multidisciplinary team.

For decades, family practitioners led care with efficiency, strong outcomes, and meaningful cost containment. That role should be restored, supported, and respected.

Primary Preventive Medicine is the cornerstone of Population Health Management. Good medical practice belongs within a multidisciplinary team led by the family practitioner, where care is coordinated, personal, and accountable.


Tony Behrman CEO CPC/Qualicare

John Paul Valentyn COO CPC/Qualicare






- Risk independent of smoking history
- Systemic inflammation amplifies CV risk
- severe COPD
- Use validated CV risk calculator (SCORE2)



ANOTHER HUGE SUCCESS

CPC/QUALICARE OPEN DAY

6 JUNE 2026





All pharmacy. All convenience. Now on WhatsApp.

At Medipost, we understand that your chronic medication is essential to managing your chronic illness.

That is why South Africa's first courier pharmacy is now offering instant support and prompt service through the Medipost Pharmacy WhatsApp chat service. You can order your medication hassle-free and have it delivered to any address in South Africa without interruption.

All you need to do is WhatsApp 012 426 4655

- Register as a patient
- Follow the prompts
- Discuss your pharmacy and health-related needs with us
- Arrange for your free delivery to your preferred address
- Chat directly to an agent
- Get instant support and service in all official languages with South Africa's first courier pharmacy.

Connect with us



012 426 4655



012 426 4000



info@medipost.co.za



medipost.co.za



Medipost app



Medipost



medipostpharmacy



medipostpharmacy

Want it? Need it? WhatsApp it.



Medipost
Pharmacy

Proudly introducing the **NEW** additions to Innovata's portfolio



New Pack Size

Reg No.: A 55/20.1.1/0733

CEPTOMAX

Azithromycin 200 mg/5 mL Suspension

Reg No.: A 57/5.7.1/0168

AVARINEX

Desloratadine 2,5 mg/5 mL Syrup



Reg No.: A 57/21.2/0121

DIAMET XR 500

Metformin Hydrochloride 500 mg XR Tablets



Reg No.: A57/21.2/0123

DIAMET XR 1000

Metformin Hydrochloride 1000 mg XR Tablets

Reg No.: A59/21.2/0253

VILDAMET 50/850

Vildagliptin 50 mg and Metformin Hydrochloride 850 mg Tablets



Reg No.: A 59/21.2/0254

VILDAMET 50/1000

Vildagliptin 50 mg and Metformin Hydrochloride 1000 mg Tablets



Reg No.: A50/7.1.3/0346

AMLOTEL 80/5

Telmisartan 80 mg and Amlodipine 5 mg Tablets



Reg No.: A 50/7.1.3/0347

AMLOTEL 80/10

Telmisartan 80 mg and Amlodipine 10 mg Tablets



Reg No.: A59/11.4.3/0325

TRUSFLUKS 20

Esomeprazole Gastro-Resistant Tablets 20 mg



Reg No.: A59/11.4.3/0326

TRUSFLUKS 40

Esomeprazole Gastro-Resistant Tablets 40 mg

Reg No.: A 57/2.2/0124

ZOPICLONE 7,5 INNOVATA

Zopiclone 7,5 mg Tablets




For full prescribing information refer to the Professional Information approved by the South African Health Products Regulatory Authority (SAHPRA).
Innovata Pharmaceuticals (Pty) Ltd., 100 Northern Parkway Rd, Crownwood Office Park Block D, Ground Floor, Ormonde, Johannesburg, 2091.
 Tel.: +27 86 999 0912. Reg. No.: 2013/093943/07. Review Number:

www.innovata.co.za [linked in](https://www.linkedin.com/company/innovata-pharmaceuticals) Innovata Pharmaceuticals.

innovata
 pharmaceuticals

QualiCare Cape Town Open Day 2026


Performance as assessed by the exhibitors



Cape Town Open Day 2026 Performance as assessmentcontinue to page 14

QualiCare Cape Town Open Day 2026

Attendance and POPIA-compliant Consent Data



SIBIONICS

SIBIONICS GS1 CGM System



-  Safe for use from 3 years old and above
-  Calibration free
-  18 million annual capacity for production
-  18-month shelf life
-  Multi-port data sharing
-  Real-time continuous monitoring
-  MARD value is 8.7%
-  14-day wear time
-  High/low glucose alerts
-  IP28 waterproof
-  All-in-one sensor+transmitter
-  Full dimensional report

SIBIONICS



Altys Technology (Pty) Ltd.

Address: 377 Rivonia Boulevard, Edenburg, Johannesburg,
Gauteng, South Africa

Email: wecare@altysgroup.com



SIBIONICS Mobile App



Get it on
Google Play



Download on the
App Store




GET IT ON
AppGallery





AGENDA TOPICS

 CPC/Qualicare Open Day, 6 June 2026		Venue: Biomedical Research Institute Tygerberg Medical School Campus, SUN	
6 Clinical & 2 Ethics CPD accredited for the day.		NB: This Agenda maybe subject to amendment without notice	
		Please watch your mass emails for latest details	
TIME	TOPIC	SPEAKER	SPONSOR
06hr45-07hr30	Welcome, Registration of Delegate: Coffee, Tea and rusks		All advertisers are invited to be present during this welcome session
	HPCSA Latest Guidelines	SIGN IN	
07hr30 - 07hr50	Latest HCPSA Guidelines on Harmful Business Practices and Perverse Incentives	Sister Letmore Chigudu	MPS South Africa Services
	Workshop on AI in Healthcare		
07hr50 - 08hr10	Ethics of using AI in Healthcare	Dr Chris Verster	Macleods Pharmaceuticals SA
08hr10 - 08hr30	The Rise of the Care Orchestrator: Doctor-Led Clinical Excellence in the AI Era	Ms Ivone Veiga-Moroldo	Healthbridge
08hr30 - 08hr50	AI in Healthcare	Dr Odwa Mazwai	Universal Care
	Workshop on Women's and Men's Health		
08hr50 - 09hr10	Womens Health: Menopause : The Window of Opportunity	Dr Malikh van der Schyff	Abbott
09hr10 - 09hr30	Womens Health: Abnormal Uterine Bleeding	Dr Malikh van der Schyff	Abbott
09hr30 - 09hr50	Benign Prostatic Hyperplasia. Guidelines and Directed Management	Dr Kent Pluke	Cipla
	Cardiometabolic Workshop Part 1		
09hr50 - 10hr10	Magnifying Multimorbidity: A Holistic Approach to Cardiometabolic Care	Dr Mahmoud Al-Naili	Servier
10hr10 - 10hr30	Quality, Weightloss and Health Gain	Dr Rust Theron	Novo Nordisk
	Workshop on Respiratory topics (Part 1) incl. COPD, Allergic Rhinitis and other Allergies		
10hr30 - 10hr50	Synergy of Platelet-Activating Factor and Histamine in Allergic Rhinitis and Urticaria	Dr Pieter De Waal	Macleods Pharmaceuticals SA
10hr50 - 11hr10	COPD Heart Lung Cross talk in COPD : Shared Biology to Bedside decisions	Dr N Voragee	AtraZeneca
11hr10 - 11hr30	Allergy fundamentals : Key Insights in Family Practice	Dr Shaunagh Emanuel	ThermoFisher
11hr30 - 12hr15	MORNING TEA & VISITS OF STALLS		
	Workshop on Medical Aid matters, Fraud Waste and Abuse: Bias in Peer Reviews section 59?		
12hr15 - 12hr35	Reportback on the Section 59 Investigation into possible Racial Bias in Peer review	Ms Sarika Besesar	Discovery
12hr35 - 12hr55	Precision and Personalization Human Centered Innovation for a healthier healthcare system	Ms Jane Ball	Discovery
12hr55 - 13hr15	Ethics in Pathlogy for GPs, Nurses and GP Sponsored Laboratories on site	Dr John Douglass	Pathcare
13hr15 - 13hr35	Detection of Fraud in General Practice	Mr Ishmael Mogapi	GEMS
13hr35 - 13hr55	Alternatives to Traditional Healthcare: Seeking and Engagement	Dr Wayne Riback	Medshield
13hr55 - 14hr55	LUNCH IS SERVED & VISITS OF STALLS		
	Workshop on Diabetes & Cardiometabolic Syndrome Part 2	SIGN IN	
14hr55 - 15hr15	Beyond Glucose: Uncovering hidden Risk	Dr Ilana Joubert	Pharma Dynamics
15hr15 - 15hr35	CaReMe in Practice: From Insight to Impact	Dr Julian Trokis	Pharma Dynamics
	Vaccine Workshop		
15hr35 - 15hr55	Don't Miss Hepatitis B: The Silent Infection Sitting in Your Waiting Room	Dr Neliswa Gogela	Gilead
15hr55 - 16hr15	Vaccination in pregnancy to protect infants from Respiratory Syncytial Virus (RSV)	Prof Benjamin Kagina	Pfizer
16hr15 - 16hr35	Rethinking Prevention: Life Course Vaccination and Pneumococcal Disease in Adults	Prof Angela Dramowski	Pfizer
	Respiratory Workshop (Part 2)		
16hr35 - 16hr55	Navigating the Role of LAMAs in the South African COPD Landscape	Prof Richard van Zyl-Smit	Glenmark
16hr55 - 17hr15	Health in Synergy: Interface between Homeopathy and Allopathic Medicine	Ms Joan van Wyngaard	Nativa
17hr15 - 17hr35	AFTERNOON TEA IS SERVED & VISITS OF STALLS	SIGN IN	
	Workshop Stress, Burnout & Building Resilience for the Future		
17hr35 - 17hr55	Building Resilience: Tools for remaining in Private Practice	Ms Hemari Bonthuys	PPS
17hr55 - 18hr15	From Stress to Burnout: Protecting the Mental Health of Private Healthcare Professionals.	Dr Qhama Cossie	Life Vincent Pallotti Hospital
18hr15 - 18hr30	Announce Prize Winners: DO NOT MISS THESE SUPER PRIZES before you leave	SIGN OUT	

VENUE

Biomedical Research Institution

GPS Coordinates 33° 54' 29.1"S 18° 36' 43.6"E

Biomedical Research Institute, Opposite P5 parking area on the Tygerberg Medical School Campus.

bebird

Reimagining Ear Care: Smart, Camera-Assisted Hygiene at Home

What if you could show your patients exactly what you see inside their ear?

Visual explanation is a powerful clinical tool, yet in ear examinations, patients are often reliant on verbal descriptions alone. Being able to demonstrate findings in real time, whether it's earwax build-up, irritation or early signs of infection, can significantly improve patient understanding and overall engagement with care. Emerging smart ear-care technologies are making this level of visualisation more accessible, both in practice and beyond.

bebird, a smart ear-care brand, has developed devices designed to enhance both precision and visibility in ear hygiene and examination. Its EarSight Plus device combines a high-definition camera with a flexible, probe-like tip and smartphone connectivity, enabling doctors to capture and display live images of the ear canal. This real-time visual feedback allows practitioners to guide patients through what is being observed, creating a more transparent and educational consultation experience.





Beyond chairside use, the technology also supports continuity of care. Through the bebird app, images and videos can be recorded and securely shared, allowing for follow-up assessments, remote guidance or patient monitoring over time. This is particularly valuable in cases of recurrent earwax impaction or ongoing ear health concerns, where visual tracking can support more informed clinical decision-making.

There is also a growing role for patient participation. With appropriate guidance, patients can use the same technology at home to better understand their ear health and maintain routine hygiene. This creates a more collaborative care model, where patients are not only informed but actively involved, while still operating within a framework of professional oversight.

The EarSight Plus is designed for versatility, with interchangeable tips suited to different users and an ergonomic, flexible design intended to support ease of use. Its intuitive interface further lowers the barrier to adoption, making it a practical addition to both clinical and at-home care settings.

Smart ear-care technologies like bebird are helping to bridge the gap between examination, education and ongoing management. By enabling doctors to visualise, document and share what was previously unseen, these tools have the potential to enhance diagnostic clarity, strengthen patient communication and support better long-term outcomes.

Effective ear hygiene remains an important component of overall patient wellbeing, yet earwax build-up and inappropriate cleaning practices continue to present frequently in clinical settings. Traditional methods, including cotton swabs and improvised tools, carry well-established risks, often pushing wax deeper into the ear canal and increasing the likelihood of discomfort, impaction or infection. In this context, tools that support safer, more precise and better-guided approaches represent a meaningful step forward in both patient care and clinical practice.

To purchase or for more information visit www.bebirdsa.co.za or <https://ivohealth.co.za/product/earsight-plus/>



- THANK YOU - TO OUR EVENT PARTNERS

DIAMOND SPONSOR

Let's test.

Trusted results.



Allergy

Want to know more about what is causing your patients' symptoms?

Enhance Patient Outcomes with ImmunoCAP™ Specific IgE tests – The gold standard in in-vitro allergy diagnostics.¹

Backed by over 50 years of research, our tests deliver precise and reliable results to support accurate allergy diagnosis and patient management.

Scan or click QR codes to learn more about our services



ImmunoCAP™ products
for healthcare professionals



Allergen Encyclopedia
for healthcare professionals



AllergyInsider
for patients & healthcare professionals

Reference: 1. Cramer R. The crux with a reliable in vitro and in vivo diagnosis of allergy. **Allergy**, 2013;68(6):693–694

© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. 447206.AL.INTERNATIONALSouth Africa.EN.V1.24

EXHIBITOR'S



DIAMOND SPONSOR



Challenging Frontiers in Healthcare

We sincerely thank the delegates who took the time to visit our exhibition stand.





Kawari Wholesaler and Distributor
**Setting the standard in professional
wholesale, distribution, and warehousing
of medications and healthcare supplies.**

Servicing healthcare providers across South Africa:

- Healthcare practices
 - Hospital groups
 - Retail pharmacies
 - Over 90 registered pharmaceutical manufacturers
 - Nursing professionals
 - Mining groups and more
- **Fully compliant with SAHPRA's Good Wholesale and Distribution Practice guidelines. Our ISO 9001 certified services are trusted for wholesale supply and delivery of scheduled and non-scheduled pharmacy, health and wellbeing products.**


Try our WhatsApp chat service on 012 426 4657 for prompt assistance with:

- Placing orders
- Product information
- Logging enquiries
- Order status updates
- Customer support
- General enquiries

Contact us today on:
WhatsApp: 012 246 4657
Telephone: 012 426 4001
Email: orders@kawari.co.za
Website: <https://kawari.co.za/>



No 1 Brand
in Germany*



NEW

Tailored vitamin and mineral support for people with diabetes

- ✔ With antioxidants (vitamin C, vitamin E, selenium)
- ✔ B-complex vitamins
- ✔ Chromium

ivohealth
 0860 456 123 | www.ivohealth.co.za | www.doppelherz.co.za
 @ivohealth @doppelherz_southafrica | doppelherz@ivohealth.co.za
 Available at selected pharmacies in South Africa and Namibia

More products



Slow-release formulation allows gradual nutrient release ensuring sustained supply that benefits absorption. Doppelherz is Germany's No. 1 brand in the general healthcare market in food retail + drugstores Source: NielsenIQ MarketTrack. Based on database general healthcare market, AGM, sales value, for the period February 2024 - January 2025, Food retail + Drugstores, Germany (Copyright © 2025, NielsenIQ (Germany) GmbH). Contents per tablet: Thiamine mononitrate (vitamin B1) 2 mg, riboflavin (vitamin B2) 1.6 mg, niacin (vitamin B3) 18 mg, calcium-D-pantothenate providing pantothenic acid (vitamin B5) 6 mg, pyridoxine hydrochloride providing pyridoxine (vitamin B6) 5 mg, cyanocobalamin (vitamin B12) 9 µg, L-ascorbic acid (vitamin C) 200 mg, DL-α-tocopheryl acetate providing D-α-tocopherol (vitamin E) 42 mg, D-biotin (vitamin H) 150 µg, folic acid 450 µg, magnesium oxide providing magnesium 200 mg, zinc gluconate providing zinc 5 mg, chromium (III) chloride providing chromium 60 µg, sodium selenate providing selenium 30 µg. Complementary medicine, health supplement for humans. This unregistered medicine has not been evaluated by SAHPRA for its quality, safety or intended use.





BUREAU | PMB | ADVISORY


The Ultimate Medical Bureau For High-Net-Worth Medical Practitioners


Allow us to unlock your wealth by elevating your net worth.

As team we work with and empower your practice staff to ensure the most favorable outcome when looking at Medical Aid reimbursements.

We handle your medical billing, so you can focus on your patients, with your Medical Practice's back-office always in our expert hands.

Contact us:

 086 147 4339

 hello@gridwealth.co.za

 www.gridwealth.co.za

#workedformywealth #poweredbygridwealth #financialfreedom



A calming touch

Introducing CLOBAZAM ADCO

Indicated for the treatment of anxiety in neurotic patients, for pre-operative medication, and it may be effective in relieving the acute symptoms of alcohol withdrawal syndrome¹

May be used as an adjuvant in epilepsy*¹

- Unlike other benzodiazepines, **CLOBAZAM ADCO** has less sedative effects²
- Mild to moderate adverse events²
- Cost saving of 15 % versus originator³





NEW

 **Clobazam**
Clobazam **ADCO**

*The dosage of CLOBAZAM ADCO should be determined by monitoring the EEG and plasma levels of the other medicines.¹

References: 1. CLOBAZAM ADCO 10 & 20 mg tablets Professional Information, 27 June 2023. 2. Faulkner MA. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome. *Ther and Clin Risk Manage* 2015;11:905-914. 3. Generics dictionary. http://www.generic.co.za/frontend/generics?uf8=-%E2%9C%933&q%5Bactive_ingredient_name_eq%5D=CLOBAZAM (Accessed: 03 October 2023).

For full prescribing information please refer to the Professional Information approved by SAHPRA (South African Health Products Regulatory Authority).

 CLOBAZAM 10 ADCO. Each tablet contains 10 mg of clobazam. Reg. No.: 552.6/0546  CLOBAZAM 20 ADCO. Each tablet contains 20 mg of clobazam. Reg. No.: 552.6/0547.

Adcock Ingram Limited, Reg. No.: 1949/034385/06 Private Bag X69, Bryanston, 2021. Customer Care: 0860 ADCOOK/232625. www.adcock.com 2023080110303342, August 2023.

adcock ingram 
generics



Keep your finger on the pulse of your practice.

We know that practice administration takes up too much of your time - time away from patient care, professional development and family. **CGM MEDEDI's Task Organiser** gives you quick access to all practice admin - **all in one place!**



Work in one place



Stay organised



Action it now

Ready to take control of your practice?

0861 633 334 • hello.za@cgm.com

CGM MEDEDI

Billing and Practice Management

INTRODUCING MyServier



Watch



Learn



Listen



The **content hub** for Healthcare Professionals

For **therapeutic content** on:

- Hypertension
- Diabetes
- Cardiovascular Disease
- Dyslipidaemia

- ✔ **Personalised dashboard**
- ✔ **Easy access** to CPD courses
- ✔ **Keep track** of courses completed
- ✔ **CPD points** earned
- ✔ Generate **instant certificates** upon completion of courses

Visit:
www.myservier.co.za
For effortless registration

Scan
here





Another Huge success CPC/Qualicare Open Day 6 June 2026continue to page 34



When staying-power counts



LASTS UP TO
36h^{1,2}

TADALAFIL ADCO for the treatment of ED¹

- Demonstrates improvement in EF for up to 36 hours post-dose^{1,2}
- Tadalafil improves psychological outcomes²
- Preferred by patients and their partners over sildenafil²

¹In a meta-analysis comparing tadalafil with sildenafil for the treatment of ED.
ED – erectile dysfunction; EF – erectile function

References: 1. TADALAFIL ADCO Professional Information, October 2022. 2. Gong B, Ma M, Xie W, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systemic review and meta-analysis. *Int Urol Nephrol* 2017;49:1731-1740.

For full prescribing information please refer to the Professional Information approved by SAHPRA (South African Health Products Regulatory Authority).

TADALAFIL 5 mg ADKO, Each film-coated tablet contains 5 mg tadalafil. Reg No.: 52/7.1.5/0084.080. TADALAFIL 20 mg ADKO. Each film-coated tablet contains 20 mg tadalafil. Reg No.: 52/7.1.5/0085.081.

Adcock Ingram Limited, Co., Reg. No.: 1949/034385/06, Private Bag X69, Bryanston, 2021. Customer Care: 0860 ADCOCK/232625. www.adcock.com
2023062910293836, July 2023.

new



Tadalafil Adco

Tadalafil 5 mg/20 mg tablets

The patient's choice for ED^{2*}

adcock ingram
generics

CGM MEDEDI
Billing and Practice Management



Practice
PERFECT

THE **PERFECT** PAIR

A centralised practice toolkit **plus** EHRs for a fully paperless practice.

www.cgm.com/za-perfectpair



Practice marketing



Online bookings



Patient onboarding



Video consults



Advanced e-Scripts



Easy payments



Medical billing



Electronic health records

Ready to take control of your practice?

Contact us on 0861 633 334 • hello.za@cgm.com



FIGHTING INFECTIONS. CHANGING LIVES.



- Broad spectrum antibiotic
- Indicated for treatment of a range of infections including lower respiratory tract infections such as community-acquired pneumonia

KLACID® XL
clarithromycin 500 mg MRT

KLACID® P
clarithromycin 125/250 mg

KLACID® I.V.
clarithromycin 500 mg powder for injection

^[S4] KLACID® P125 Granules for Suspension. Each 5 mL contains 125 mg of clarithromycin. Reg. No.: 28/20.1.1/0035. Botswana: ^[S2] Reg. No.: BOT9900333; Ghana: POM Reg. No.: FDA/SD.183-2087; Kenya: POM Reg. No.: H98/208; Malawi: POM Reg. No.: PMPB/PL147/11; Mauritius: POM Reg. No.: R4134/02/16; Namibia: ^[NS2] Reg. No.: 04/20.1.1/1269; Uganda: POM Reg. No.: 2469/06/98; Zambia: POM Reg. No.: 128/004; Zimbabwe: PP Reg. No.: 2000/7.2.5/3797. ^[S4] KLACID® P250 Granules for Suspension. Each 5 mL contains 250 mg of clarithromycin. Reg. No.: 29/20.1.1/0190. Botswana: ^[S2] Reg. No.: BOT9900334; Ghana: POM Reg. No.: FDA/SD.183-2088; Kenya: POM Reg. No.: H98/258; Malawi: POM Reg. No.: PMPB/PL147/12; Mauritius: POM Reg. No.: R3362/02/16; Namibia: ^[NS2] Reg. No.: 04/20.1.1/1270; Nigeria: POM Reg. No.: 04-3449; Uganda: POM Reg. No.: 2470/06/98; Zambia: POM Reg. No.: 128/005; Zimbabwe: PP Reg. No.: 2000/7.2.5/3798. ^[S4] KLACID® XL Modified release tablets. Each tablet contains 500 mg clarithromycin. Reg. No.: 31/20.1.1/0379. Botswana: ^[S2] Reg. No.: BOT0100451; Ghana: POM Reg. No.: FDA/SD.183-2090; Kenya: POM Reg. No.: H2001/0072; Malawi: POM Reg. No.: PMPB/PL147/13; Mauritius: Reg. No.: R3363/0 2/16; Namibia: ^[NS2] Reg. No.: 04/20.1.1/1271; Nigeria: POM Reg. No.: 04-4407; Uganda: POM Reg. No.: 5977/06/07; Zimbabwe: PP Reg. No.: 98/7.2.5/3451. ^[S4] KLACID® I.V. Lyophilised Powder for Injection. Each vial contains 500 mg clarithromycin. Reg. No.: 28/20.1.1/0264. Ghana: POM Reg. No.: FDA/SD.183-3137; Kenya: POM Reg. No.: H98/207; Mauritius: Reg. No.: R4133/02/16; Namibia: ^[NS2] Reg. No.: 10/20.1.1/0337; Tanzania: POM Reg. No.: TZ19H0188; Zimbabwe: PP Reg. No.: 2001/7.2.5/3956.

For full prescribing information, refer to the Professional Information approved by the Medicines Regulatory Authority.

Abbott Laboratories S.A. (Pty) Ltd. 1940/014043/07. Abbott Place, 219 Golf Club Terrace, Constantia Kloof, 1709. Tel: (011) 858 2000. Publication date: June 2024. Promotional review number: SAF2184909-3.



GEMS Flu and Pneumococcal Vaccine

Timely vaccination remains one of the most effective ways to protect members from severe respiratory infections.



GEMS Flu Vaccine

The Flu Vaccine is covered from the risk benefit for GEMS members and their dependants. Vaccination against the flu remains the best defence.

GEMS Flu Vaccine Benefits:

- ✓ *The flu vaccine is paid from the Risk benefit and will not deplete members' savings or day-to-day benefits.*
- ✓ *Available to all GEMS members and their dependants across ALL options.*
- ✓ *One flu vaccine per beneficiary per benefit year for everyone 6 months and older.*

Administration Tariff Codes:

Discipline	Administration codes	Notes
General Practitioner	0017	To be charged together with the Vaccine NAPPI codes if there was no consultation
Pharmacy	0022	To be claimed on the same script number as the Vaccine NAPPI code
Nurse	99378	To be charged together with the Vaccine NAPPI codes if there was no consultation

Flu Vaccine: Once per year per beneficiary.

GEMS Pneumococcal Vaccine

Vaccination against pneumococcal disease remains the best defense. Please encourage your patients to get vaccinated.

GEMS Vaccine Benefits

The Pneumococcal vaccine claims for eligible beneficiaries will be paid from preventative risk-benefits and will not affect members' savings or day-to-day benefits across ALL options.

Beneficiaries are considered high-risk if they are above 65 years of age with or without any chronic illness or below 65 with one or more of the following conditions:

- *Chronic heart disease, including congestive heart failure and cardiomyopathies.*
- *Chronic lung diseases such as chronic obstructive pulmonary disease, asthma, emphysema (chronic lung disease secondary to smoking)*
- *Diabetes mellitus*
- *Cerebrospinal fluid leaks*
- *Cochlear implant(s)*
- *Alcoholism*
- *Chronic liver disease*
- *Immunodeficiencies acquired at birth or later in life, such as HIV infection.*
- *Chronic renal failure or nephrotic syndrome Various types of Cancer such as Leukaemia, Lymphoma, multiple myeloma, Hodgkin's disease, or other generalised and metastatic malignancies*
- *Medication-induced immunosuppression because of treatments such as radiation therapy, chemotherapy, and long-term use of corticosteroids*
- *Solid organ transplant*

Visit www.gems.gov.za/Healthcare-Providers/Preventative-screening for applicable tariff codes.

DISCOVER THE
BRILLIANCE
OF
GEMS


Contact details

- 📞 0860 43 6777
- ✉ enquiries@gems.gov.za
- 🌐 www.gems.gov.za

- 📺 @GEMSMEDICALAID1
- 📺 @GEMSMEDICALAID
- 📺 Government Employees Medical Scheme



Use the QR Code to download the GEMS Practitioner App





Another Huge success CPC/Qualicare Open Day 6 June 2026continue to page 40





DOCTOR 360°

Enhancing and protecting the person behind the profession

Discovery cares about your wellbeing and brings you **precision-designed offerings, personalised for your needs**, and created exclusively for doctors, to proactively enhance your overall wellbeing, through **financial management, physical health, and mental wellness**. We invite you to discover this new dimension of care.

 FINANCIAL 360°

 PHYSICAL 360°

 EMOTIONAL 360°

FINANCIAL 360°

This bespoke benefit offering provides **doctors in both the public and private sectors** with access to a range of **flexible and holistic financial solutions**.

WORTH
make your money matter

Finance Academy is a uniquely customised, digitally enabled, financial education course offering bought to you by **Healthy Company for Doctors and Worth**. This **CPD accredited 18 course** offering provides doctors with personal and professional financial training.



Scan the QR code and sign up today.

WELL

WELL by Merchant Capital is a business funding solution created for healthcare professionals. As a valued healthcare professional applying through Discovery Health, you get **exclusive access to preferential rates and a seamless application process**.



Call **010 140 3242** or click on card for more information.

PHYSICAL 360°

Customise your **fitness routine to match your lifestyle and earn rewards** through **Vitality Active Rewards**, the world's leading in-app programme.

Vitality Active Rewards for Doctors is an exclusive in-app wellness programme for doctors, available **free of charge**. Sign up today by scanning the QR code and earn Discovery Miles for going the extra mile. **Click on card for more information**.



Scan the QR code and sign up today.

EMOTIONAL 360°

Don't suffer in silence; let's help you **prioritise your mental health** with the offering below, available **free of charge**.

The Young Doctor Mental Health Helpline gives you free access to mental health support.

- Providing **free telephonic counselling**, nationwide referrals and information to all medical students and young doctors
- **24-hour service**, open 7 days a week, 365 days a year
- Providing **crisis intervention and suicide prevention**
- **Assisting with all mental health issues** (depression, anxiety, trauma, substance abuse, bipolar, OCD, ADHD, etc)



Make your mental health a priority. Call **0800 323 323**.

NEW LAUNCH

Vyfocis

Lisdexamfetamine dimesilate
30 mg; 50 mg; 70 mg

When **focus** feels possible,
my potential feels limitless.^{1,2}



The prodrug design of **Vyfocis** delivers effective
therapeutic action for **13 to 14 hours**.³

References:

1. Banaschewski, T., Soutullo, C., Lecendrex, M. et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. *CNS Drugs* 27, 829–840 (2013).
2. Adler, L.A. et al Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. *J. Clin. Psychiatry* 74, 694–702 (2013).
3. Ermer, J. C., et al. (2016). Lisdexamfetamine dimesylate: Prodrug delivery, amphetamine exposure and duration of efficacy. *Clinical Drug Investigation*, 36(5), 341–356.

³⁰Reg. No. 37/1.6/1238. VYFOCIS 30. Each capsule contains 30 mg lisdexamfetamine dimesilate.

⁵⁰Reg. No. 37/1.6/1240. VYFOCIS 50. Each capsule contains 50 mg lisdexamfetamine dimesilate.

⁷⁰Reg. No. 37/1.6/1242. VYFOCIS 70. Each capsule contains 70 mg lisdexamfetamine dimesilate.

For full prescribing information, refer to the Professional Information approved by the medicines regulatory authority.



Lumont CO
 Montelukast 10 mg + Levocetirizine dihydrochloride 5 mg Tablets



Breathe Free. Live Free.

Dual action relief from allergies.^{1,2}
 Montelukast 10 mg + Levocetirizine dihydrochloride 5 mg

Indications⁷

Relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults (≥ 18 years of age).

Lievocam
 Lornoxicam 8 mg tablets

**RELIEF
 REDESIGNED**

Indications⁷


- Short-term treatment of mild to moderate pain associated with extra-articular inflammation
- Symptomatic treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis



^{S3} LIEVOCAM 8 mg (film-coated tablets). Each film-coated tablet contains 8 mg lornoxicam. Contains sugar (lactose monohydrate). Reg. No.: A56/3.1/1150. For full prescribing information refer to the SAHPRA approved package insert.

^{S3} LUMONT CO 10 mg/5 mg (film-coated tablets). Each film-coated tablet contains 10 mg montelukast (as montelukast sodium) and 5 mg levocetirizine dihydrochloride. Contains sugar (lactose monohydrate) Reg. NO.: A54/5.7.1/0174. For full prescribing information refer to the SAHPRA approved package insert.


Zydus Healthcare SA (Pty) Ltd. Southdowns Office Park, 22 Karee Street, Centurion, 0157. Co. Reg. No.: 1998/014338/07. Tel: +27(0)12 748 6400. **A75/LIE/LUM/05/26/PRO**



This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during May 2026 (epidemiological weeks 19-22). The data is dependent on submission of samples by clinicians and therefore may not be representative of the general population but is intended to identify trends in the circulation of these viruses which may be of clinical relevance.


INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS (RSV) AND SARS-COV-2

- Further increases in the detection rates of both influenza and RSV were noted during May, following the simultaneous start of both seasons in week 11 (week starting 9 March).
- Influenza A positivity rates increased from 23% in week 18 (week starting 27 April) to 26% in week 22 (week starting 25 May). Both A/ H1 and A/H3 subtypes continued to circulate concurrently at 46% and 54% of typed isolates respectively.
- The influenza B detection rate increased to 4% in week 22, having ranged from 1-2% during April.
- The combined RSV detection rates ranged from 15-19% during May. The percentage of samples testing positive for RSV was 47% in those aged <6 months, 45% in 6-12 month olds, and 31% in children aged 1-5 years. The percentage of samples testing positive for RSV was 6% for patients aged 6 years and older.
- The SARS-CoV-2 detection rate ranged from 1-3%, similar to the previous reporting period.




OTHER RESPIRATORY VIRUSES

- Slight decreases were noted in the positivity rates of the parainfluenza viruses and rhino/enteroviruses, however, rhino/enteroviruses remained the most commonly detected viruses during May (31-37%). No marked changes were noted in the positivity rates of the other respiratory viruses.
- For the parainfluenza viruses for which molecular typing was available, the distribution of types 2 (27%), 3 (31%) and 4 (24%) remained at similar proportions to the previous month, with parainfluenza virus type 1 at 17%.
- Among the endemic coronavirus, NL63 continued to predominate but dropped from 75% to 47% of isolates for which molecular typing was available, with increasing proportions of coronavirus HKU1 (28%) and coronavirus OC43 (22%).



ATYPICAL BACTERIA

- During May, 15 *Bordetella pertussis* cases were detected. Cases were detected from Gauteng (n=4), KwaZulu-Natal (n=4), Western Cape (n=2), Free State (n=2), North West (n=1), Eastern Cape (n=1) and Mpumalanga (n=1). Regarding age distribution, six cases were in children aged ≤5 years, five were aged 6-18 years, and four were aged >18 years. *Bordetella pertussis* is a vaccine-preventable disease, a notifiable medical condition, and post-exposure prophylaxis is recommended for close and vulnerable respiratory exposed contacts.
- Chlamydia pneumoniae* and *Mycoplasmoides pneumoniae* detection rates remained below 1%.
- A higher than average number of *Bordetella parapertussis* cases continued to be seen in May, with 34 positive samples. This included isolates from Gauteng (n=12), the Western Cape (n=10), KwaZulu-Natal (n=6), Northern Cape (n=3), Free State (n=2), and the Eastern Cape (n=1). The majority of cases were children aged 1-5 years (n=21), with a further twelve cases in children aged <1 year, and a single case aged 6-12 years. *B. parapertussis* typically presents with milder symptoms than *B. pertussis* and has less outbreak potential, therefore no prophylaxis is advised and there is currently no vaccine available. Droplet precautions should be implemented for managing these cases.
- Three *Legionella pneumophila* cases were detected during May, with two cases from the Western Cape and one from Gauteng. All three cases were in adult patients, including two in adults aged ≥65 years. *Legionella pneumophila* is a notifiable disease and these statistics represent only molecular testing for *Legionella pneumophila*, as legionella urinary antigen results are not included in this report.





THANK YOU TO ALL OUR PARTICIPATING COMPANIES AND SPEAKERS FOR SHARING YOUR INSIGHTS AND EXPERTISE.

WE APPRECIATE YOUR CONTRIBUTION TO THE SUCCESS OF OUR EVENT!



Big thank you to our amazing prize sponsors for their generous support ! 🎉 We're thrilled to share some photos of our lucky prize winners ! 🏆 #prizewinners #eventsponsor #thankyou





ERASE DATA

DOCUMENT SHREDDING SPECIALISTS

PROTECT YOUR BUSINESS WITH

SECURE SHREDDING



SECURE SHREDDING

On-Site & Off-Site Shredding



EraseData offers professional on-site and off-site shredding services designed to help businesses securely dispose of confidential documents.

Our mobile shredding truck comes directly to your location, ensuring that sensitive information is destroyed safely and efficiently.

Book Your Shredding Service Today!



SCAN ME



Unit 1, 1B Sapphire Street
Bellville South, Cape Town

www.erasedata.co.za



+27 10 500 7674

+27 68 783 4936

embecta is dedicated to improving the lives of people with diabetes

Our **mission** is to develop and provide solutions that make life better for people living with diabetes.

Our **vision** is a life unlimited by diabetes.



A leader in meeting the needs of people with diabetes



>8 billion

Injection devices produced annually



3

Manufacturing facilities around the globe supplying high-quality products



~30 million

People living with diabetes worldwide who use our products



>100

Countries where our products are sold



2000+

Employees committed to improving diabetes care globally

Advance every day together™



embecta and the embecta logo are trademarks of embecta Corp. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners. © 2025 Embecta Corp. All rights reserved. Embecta South Africa (Pty) Ltd, Company Reg No: 2021/779162/07, 173 Oxford Road, Rosebank, 2196, Johannesburg, South Africa, EMB-05490, Expiry Date: 28 July 2027



BMW Century City



Discovery



PPS WEALTH ADVISORY




PPS WEALTH ADVISORY

LUCKY WINNERS,
BIG SMILES



NETCARE



MEDIS We're turning 30!



TRINITY PHARMA



e|elle simplifying practice management



2 INDICATIONS, 1 VACCINE¹

ABRYSVO[®]
Recombinant respiratory syncytial virus pre-fusion F protein vaccine

 INFANTS via maternal immunisation*

 OLDER ADULTS[†]

EVERY BREATH MATTERS.

INDICATIONS



Passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy.

60+

Active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV.

*Active immunisation of pregnant women between 28 and 36 weeks gestation.¹ †Active immunisation of individuals aged 60 years and above.¹

ABRYSVO should be used in accordance with official recommendations.¹

Help protect infants, via maternal immunisation, and older adults against RSV.¹

To report an adverse event, please contact ZAF.AEReporting@pfizer.com. If you wish please use contact details below. +2711 320 6000 or 0860 734 937 (SA). Monday-Friday 09h00-17h00

Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).

Reference:
1. ABRYSVO Local Product Document. 10 December 2024

PP-A1-ZAF-0166




Scan the QR Code for full prescribing information

Images for illustration purposes only.



YOU WON!
We Celebrate



**NOW available
in South Africa**

VEMLIDY for the flow of life with chronic hepatitis B¹


Vemlidy[®]
tenofovir alafenamide 25mg
tablets



VEMLIDY is indicated for:

The treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg with compensated hepatic disease /function.¹

Each film-coated tablet contains 25 mg of tenofovir alafenamide.¹



Reference: 1. Vemlidy Professional Information approved by the Medicines Regulatory Authority 19 June 2025.

For full prescribing information refer to the professional information approved by the Medicines Regulatory Authority. S4 VEMLIDY 25 mg film-coated Tablets. Reg. No.: 52/20.2.8/0273. Each film-coated tablet contains tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide. Contains 95 mg lactose (as monohydrate). Gilead Sciences South Africa (Pty) Ltd., Reg No.: 2014/063761/07, Ground Floor Mac Mac Building, Maxwell Office Park, Magwa Crescent, Waterfall. (Tel: +27 10 346 1920). For any adverse events, please contact: Safety_FC@gilead.com VEMLIDY[®], the VEMLIDY[®] Logo, GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc. or its related companies. All other trademarks referenced herein are the property of their respective owners. ©2025 Gilead Sciences, Inc. All rights reserved. Date of preparation: 07/2025 Job code: ZA-VEM-0017.





TRINITY PHARMA
WINNING MOMENTS TO TREASURE!



We are truly grateful for your participation in our 29th Face-to-Face Qualicare Open Day. Your involvement was key in making the event both memorable and a great success.

Thank you for your continued support.

A GIANT OF MEDICINE, FAILED BY JUSTICE



A GREAT tree has fallen in the forest.

Professor Cyril Karabus passed away on Tuesday, June 9, 2026.

The residents of Cape Town will recall that Independent Newspapers reported on the incarceration of Professor Karabus from August 18, 2012.

Both the Argus and the Cape Times newspapers had a daily report of this unlawful incarceration.

Prof Karabus had had an illustrious career with over 40 years treating paediatric patients at the Red Cross Hospital in Cape Town.

He was previously the head of the Department of Paediatrics and Child Health at the hospital.

During his career he treated literally thousands of children, mostly from the Cape Flats.

He was a well-known medical personality in Cape Town and beyond.

Karabus's incarceration in Abu Dhabi on August 18, 2012 was a shock to him and his family.

He was in transit at the Dubai International Airport after having attended his son's wedding in Canada.

It would take almost nine months after waging an international campaign with support from the Jewish, Muslim and Christian communities before we were able to get him home.

51

A giant of medicine, failed by justicecontinue to page 52

Professor Karabus was a highly respected doctor with an international reputation.

As a Professor Emeritus of Paediatrics at UCT and a former head of the Oncology and Haematology unit at the Red Cross Hospital, the whole situation was unbelievable.

As a specialist in both paediatrics and oncology, he taught generations of medical students at Red Cross.

He was absolutely devoted to caring for children with cancer and he had spent his whole life saving young lives.

I spent nine months contacting everyone whom I believed would be helpful.

Literally thousands of people came forward to offer advice and to support the fundraising to ensure that Professor Karabus received the best legal advice in Abu Dhabi.

They required a retainer deposit of over R1 million and there would be a further million to be paid for “blood money”.

We received help from individuals such as Professor Heather Zar, Head of the Department of Paediatrics and Child Health at the Red Cross Children’s Hospital, and from the late Professor Solly Marks.

The South African Medical Association (SAMA) were helpful, as was the Treatment Action Campaign.

One of the concerned people who offered to help was a former student of Prof Karabus, Dr Iqbal Survé of the Sekunjalo Group who flew to Abu Dhabi and appealed to high intermediaries to approach the Crown Prince Sheikh Mohammed bin Zayed.

Dr Survé had used his knowledge of how things work in the Middle East to be part of a team clearing Prof Karabus through the Medical Committee of Abu Dhabi.

Dr Grootboom, the chairman of SAMA at the time, and Dr Sonderup helped immensely. This ordeal was an absolute travesty of justice and it was like a replay of Kafka’s ***The Trial***.

Prof Karabus is survived by his wife Jenny and his five children.

Condolences from CPC/Qualicare to all family and friends of Professor Cyril Karabus.



► Private Clients

Your private banking experience from Nedbank



see money differently

NEDBANK

Nedbank Private Clients offers the following:

- A team of financial specialists with extensive medical industry experience who can support and guide you as you start to build your wealth.
- A dedicated relationship banker.
- Preferential lending and investment rates.
- A 110% home loan for first-time home buyers.
- Travel and lifestyle perks.
- Access to wealth solutions.

No fees for students in their final year until the end of the academic year on 31 December 2025. If you are younger than 30 and a qualified medical professional earning a salary, you will receive a 50% discount on your monthly fees.

Once you have been placed by the Department of Health by the end of December, you may be eligible for the following facilities at preferential interest rates, subject to approval*:



A credit card



Vehicle finance



An overdraft



Property finance

If you are an existing Nedbank client with an account we can upgrade your existing account while giving you the same great benefits.

We look forward to partnering with you on your journey to success.

Enjoy the complete private-banking experience with Private Clients from Nedbank. Digital when you want it. Human when you need it.

For more information:



+27 10 214 7820



medical@nedbank.co.za



Invitation to Dentists, Physiotherapists and Allied Health Care Professionals to become an Associate Member of CPC/QUALICARE

Dear Colleagues,

As we approach the new era of increased Government involvement in Health Care Delivery, we anticipate an increase in the speed of implementation of NHI Holding membership of the CPC/Qualicare Network, the largest and most widely representative Medical Network of Healthcare Providers in the Western Cape comprising Doctors, Dentist and Allied Health Care Professionals alike will, we believe, stand in good stead as Government looks to setting up the new Health Care Delivery system for South Africa.

Associate members of CPC/Qualicare offers you the following opportunities:

- Full access to our Monthly newsletter in electronic format.
- Free advertising in our monthly newsletter of your practice related information (max 200 words).
- Free advertising for a locum service, with no commission charges payable.
- Reduced fees to attend our CPC/Qualicare function, at Associate Member's rate.
(Approximately 30% lower than Non-members rates)
- CPC/Qualicare is committed to providing our members and shareholders with all of their CPC requirements each year. Associate Members receive reduced cost of CPD offerings and other CME offerings compared to non-member rates.
(Approximately 30% lower than non-member rates).
- Free listing your practice as part of CPC/Qualicare's Western Cap Electronic Network, your practice will be listed as part of CPC/Qualicare at no charge.
(Worth R6000.00 per annum)
- 2 Free stationary items worth R150.00 per month in the form of 1 Prescription pad - 100 leaves, 1 Sick certificate pad - 100 leaves and the ability to purchase further stationary at 30% below current market prices.
- Preferential rates on certain Practice management software systems depending on vendor.
- Inclusion into the CPC/Qualicare Mass email service to receive important health care updates.
- Certain personal banking offerings from commercial banks.
- NHI future possibilities for your practice...Watch this space as NHI starts to roll out!!
- Preferred wholesale and facilitation of opening new accounts with them.
- Assistance with registration of an Integrated Pollution and Waste Information System IPWIS off the Western Cape Government.
- Assist with late medical aid payments, claw-backs, and withholds, as well as advice on practice admin and responses to forensic investigations.

Cost of Associate Membership

- Dentist R355.00 VAT inclusive, per month
- Allied Health Care Professionals R355.00 VAT inclusive, per month

All fees payable by debit order only. Minimum membership period is 12 months with a 3-month notice period thereafter.

Please note that we also offer reduced membership fees for **first time Medical Practitioners (GP's)** in **private practice** for their first year of membership.

Should you be interested in this offering, please email Louna at pa@cpcqualicare.co.za and one of our 5 consultants will make contact with you shortly.

Warm regards,

Dr. Tony Behrman, CEO of CPC/Qualicare

Qualicare Electronic Doctor Network.

Free electronic listing (valued at R6,000.00 per year) of your practice, geographic location, special areas of interest and pictures of your practice can be featured on our Electronic Doctor Network which is only available to CPC/Qualicare Members and Shareholders!!

Our highly successful electronic doctors network see www.qualicaredoctors.co.za has rapidly expanded across the Western Cape Province, and to date has approximately 200 doctors.

As a Member or Shareholder you are still entitled, **at NO charge**, to list your practice on the "EDN" showing your name, practice name, GPS coordinates, areas of special interests, and any specific features which you would like to bring to the attention to prospective patients then please complete and return the form below at your earliest convenience should you be interested to join the growing network.

This is a limited offer open only to Shareholders and Members which is worth over R6,000.00 per year and is brought to you as a member or shareholder benefit at no charge.

Practitioners Details

*** Compulsory to complete – for a successful listing.**

*First Name: _____

*Surname: _____

*Professional Degrees e.g. M.B.ChB. _____

Professional Body Memberships: _____

*HPCSA Number: _____

*Board of HealthCare Funders PCNS Number: _____

DOH Disp Lic Number (if applicable): _____

Areas of Special Interest and Focus: e.g. Paediatrics, Bariatrics, Occupational Health: _____

Contact Details

*Contact Number: (Practice) _____

*Email Address: _____

*Alternative Number: _____

Fax number: _____

Practice Details

*Practice Name: _____

Group PCNS: _____

*Practice Address: _____

GPS Location: _____

Please also provide:

1. **Photo of yourself** - So that the patient can familiarize themselves with the Dr they are going to see.
2. **Photo of the outside of the Practice** – So the patient will recognize the correct building and know what to look out for when coming to visit the practice.
3. **A short bio – interests, hobbies & education** – This gives the patient some trust as they will feel they know you and will feel at home.

Please feel free to contact Annerè van Pletsen CPC/Qualicare Consultant at annere@cpcqualicare.co.za

I permit CPC/Qualicare to list my name, surname, the name of my practice, my practice details, and further details provided by me in this application, and my GPS Coordinates on the “Electronic CPC/Qualicare Doctor Network” at no cost to me or my practice (tick the appropriate block).

Yes I do agree to the above, in terms of POPIA Act 4 of 2013

Click on the link to complete the form:

<https://www.qualicaredoctors.co.za/new-form/>



QualiCare



01 May 2026 - 31 May 2026



Summary

Reported period	Month May 2026				
First visit	01 May 2026 - 00:14				
Last visit	31 May 2026 - 23:54				
	Unique visitors	Number of visits	Pages	Hits	Bandwidth
Viewed traffic *	4,186	5,572 (1.33 visits/visitor)	15,269 (2.74 Pages/Visit)	58,505 (10.49 Hits/Visit)	47.84 GB (9003.38 KB/Visit)
Not viewed traffic *			10,862	30,681	18.10 GB



Disclaimer:

The entire contents of the CPC/Qualicare Newsletter is based upon the latest and most up to date information at the time of sending.

Due to the fluency of the situation, information changes daily. Please visit our website for more updated information.

This Newsletter is subject to the provisions of the Protection of Personal Information (POPI) Act (Act 4 of 2013), as well as the General Data Protection Regulations of the European Union (GDPR EU). The content of this site and/or attachments, must be treated with confidentiality and only used in accordance with the purpose for which they are intended.

Neither CPC/Qualicare (PTY)LTD or CPC Holdings (PTY)LTD, their Directors & staff accept any liability whatsoever for any loss, whether it be direct, indirect or consequential, arising from information made available in this Newsletter or actions resulting therefrom. Any disclosure, re-transmission, dissemination or any other use of this information is prohibited.

Images & Articles:

Articles:

1. <https://www.pressreader.com/south-africa/cape-argus/20260615/281578067359436>

Images:

www.canva.com

1. <https://t.prcdn.co/img?regionKey=IntzMIMITCOUkrNVvkef9g==&scale=330>



THE END

59